Glaucoma implant with therapeutic agents

• US 20040127843A1
• Filed: 11/12/2003
• Published: 07/01/2004
• Est. Priority Date: 04/14/2000
• Status: Active Grant

• Current Assignee: DOSE Medical Corporation (Glaukos Corporation)
• Original Assignee: Glaukos Corporation
• Inventors: Tu, Hosheng, Haffner, David, Niksch, Barbara, Smedley, Gregory
• Granted Patent: US 7,708,711 B2
• Time in Patent Office: Days
• US Class Current: 604/27
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2430/16 for reconstruction of eye parts, e.g. intraocular lens, cornea
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61M 27/002 Implant devices for drainage of body fluids from one part of the body to another intraocular A61F9/00781; middle ear A61F11/202

Abstract

Devices and methods are provided for the treatment of glaucoma. An ocular implant is adapted such that aqueous humor flows controllably from the anterior chamber of the eye to Schlemm'"'"'s canal, bypassing the trabecular meshwork. The implant may utilize one or more bioactive agents effective in treating glaucoma or other pathology.

Claims

1. An implant for treating glaucoma, comprising:

a body comprising material that includes a drug, said body having an inlet portion and an outlet portion, said inlet portion configured to transport fluid from the anterior chamber of an eye to the outlet portion when the outlet portion is disposed in Schlemm'"'"'s canal of the eye, said outlet portion having an outflow opening.

2. The implant of claim 1, wherein said body is coated with said drug.

3. The implant of claim 1, wherein said drug comprises heparin.

4. An implant for treating glaucoma, comprising:

a body having a bioactive agent in or on said body, said body having an inlet portion and an outlet portion, said inlet portion configured to transmit fluid from the anterior chamber to the outlet portion when the outlet portion is disposed in Schlemm'"'"'s canal, said outlet portion having an outflow opening.

5. The implant of claim 4, wherein said body is coated with said bioactive agent.

6. The implant of claim 4, wherein said bioactive agent comprises heparin.

7. The implant of claim 4, wherein said bioactive agent comprises TGF-beta.

8. The implant of claim 4, wherein said bioactive agent comprises a gene.

9. The implant of claim 4, wherein said bioactive agent comprises an anti-inflammatory drug.

10. The implant of claim 4, wherein said bioactive agent comprises an intraocular pressure-lowering drug.

11. The implant of claim 4, wherein said bioactive agent comprises a growth factor.

12. The implant of claim 4, wherein said bioactive agent comprises an antiproliferative agent.

13. The implant of claim 4, wherein said bioactive agent is loaded onto a surface of the outlet section.

14. The implant of claim 4, further comprising a biodegradable material in or on said implant.

15. The implant of claim 14, wherein the biodegradable material is selected from the group consisting of poly(lactic acid), polyethylene-vinyl acetate, poly(lactic-co-glycolic acid), poly(D,L-lactide), poly(D,L-lactide-co-trimethylene carbonate), collagen, heparinized collagen, poly(caprolactone), poly(glycolic acid), and a copolymer.

16. The implant of claim 4, wherein the outlet end further comprises a plurality of pillars at said outlet end.

17. The device of claim 16, wherein the bioactive agent is in or on at least one of said pillars.

18. The implant of claim 4, wherein said implant is at least partially coated with at least one polymer film that contains the bioactive agent, said polymer film permitting a delivery of a quantity of the bioactive agent to ocular tissues over time.

19. An ocular implant comprising:

a body having a bioactive agent in or on said body, said body further comprising;

an inlet section configured to be positioned in the anterior chamber of an eye;

an outlet section configured to be positioned at least partially in Schlemm'"'"'s canal of said eye, said outlet section being in fluid communication with said inlet section;

a lumen extending between said inlet section and said outlet section; and

a flow-restricting member within the lumen, said flow-restricting member being configured to prevent at least one component of blood from passing through the flow-restricting member.

20. The implant of claim 19, wherein said body is coated with said bioactive agent.

21. The implant of claim 19, wherein said bioactive agent comprises heparin.

22. The implant of claim 19, wherein said bioactive agent comprises TGF-beta.

23. The implant of claim 19, wherein said bioactive agent comprises a gene.

24. The implant of claim 19, wherein said bioactive agent comprises an anti-inflammatory drug.

25. The implant of claim 19, wherein said bioactive agent comprises an intraocular pressure-lowering drug.

26. The implant of claim 19, wherein said bioactive agent comprises a growth factor.

27. The implant of claim 19, wherein said bioactive agent comprises an antiproliferative agent.

28. The implant of claim 19, wherein said bioactive agent is loaded onto a surface of the outlet section.

29. The implant of claim 19, further comprising a biodegradable material in or on said implant.

30. The implant of claim 29, wherein the biodegradable material is selected from the group consisting of poly(lactic acid), polyethylene-vinyl acetate, poly(lactic-co-glycolic acid), poly(D,L-lactide), poly(D,L-lactide-co-trimethylene carbonate), collagen, heparinized collagen, poly(caprolactone), poly(glycolic acid), and a copolymer.

31. The implant of claim 19, wherein said bioactive agent comprises an Imidazole antiproliferative agent.

32. The implant of claim 19, wherein said bioactive agent comprises a quinoxaline.

33. The implant of claim 19, wherein said bioactive agent comprises a phsophonylmethoxyalkyl nucleotide analog.

34. The implant of claim 19, wherein said bioactive agent comprises a potassium channel blocker.

35. The implant of claim 19, wherein said bioactive agent comprises a synthetic oligonucleotide.

36. The implant of claim 19, wherein said bioactive agent comprises 5-[1-hydroxy-2-[2-(2-methoxyphenoxyl)ethylamino]ethyl]-2-methylbenzenesulfonamide.

37. The implant of claim 19, wherein said bioactive agent comprises a guanylate cyclase inhibitor.

38. The method of claim 37, wherein the guanylate cyclase inhibitor in selected from the group consisting of methylene blue, butylated hydroxyanisole, and N-methylhydroxylamine.

39. The implant of claim 19, wherein said bioactive agent comprises 2-(4-methylaminobutoxy) diphenylmethane.

40. The implant of claim 19, wherein said bioactive agent comprises a combination of apraclonidine and timolol.

41. The implant of claim 19, wherein said bioactive agent comprises a cloprostenol analog or a fluprostenol analog.

42. The implant of claim 19, wherein said bioactive agent comprises a crosslinked carboxy-containing polymer, a sugar, and water.

43. The implant of claim 19, wherein said bioactive agent comprises a non-corneotoxic serine-threonine kinase inhibitor.

44. The implant of claim 19, wherein said bioactive agent comprises a nonsteroidal glucocorticoid antagonist.

45. The implant of claim 19, wherein said bioactive agent comprises a prostaglandin analog or a derivative thereof.